GNI Group Ltd. (2160.T)
JPY 3460.0
(2.37%)
JPY 3460.0
(2.37%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 8.09 Billion JPY | 1032.24% |
| 2022 | -868.25 Million JPY | -1671.7% |
| 2021 | 55.24 Million JPY | -95.61% |
| 2020 | 1.25 Billion JPY | 99.73% |
| 2019 | 629.91 Million JPY | 227.79% |
| 2018 | 192.17 Million JPY | 209.68% |
| 2017 | -175.2 Million JPY | 65.85% |
| 2016 | -513.1 Million JPY | 17.66% |
| 2015 | -623.15 Million JPY | -90.01% |
| 2014 | -327.95 Million JPY | 55.12% |
| 2013 | -730.77 Million JPY | -51.53% |
| 2012 | -482.25 Million JPY | -10.75% |
| 2011 | -435.45 Million JPY | -68.72% |
| 2010 | -258.08 Million JPY | 0.0% |
| 2008 | -1.36 Billion JPY | -6.79% |
| 2007 | -1.27 Billion JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.12 Billion JPY | -177.3% |
| 2024 Q1 | 1.45 Billion JPY | -75.27% |
| 2023 Q2 | 1.66 Billion JPY | 586.24% |
| 2023 Q3 | 554.46 Million JPY | -66.63% |
| 2023 FY | 8.09 Billion JPY | 1032.24% |
| 2023 Q1 | -341.74 Million JPY | 71.35% |
| 2023 Q4 | 5.88 Billion JPY | 960.64% |
| 2022 Q1 | 72.28 Million JPY | 108.82% |
| 2022 Q3 | 126.49 Million JPY | 0.69% |
| 2022 Q4 | -1.19 Billion JPY | -1042.84% |
| 2022 FY | -868.25 Million JPY | -1671.7% |
| 2022 Q2 | 125.63 Million JPY | 73.79% |
| 2021 Q3 | 352.96 Million JPY | -30.63% |
| 2021 Q1 | 432.54 Million JPY | -45.33% |
| 2021 Q2 | 508.78 Million JPY | 17.62% |
| 2021 FY | 55.24 Million JPY | -95.61% |
| 2021 Q4 | -819.65 Million JPY | -332.22% |
| 2020 Q1 | 132.35 Million JPY | 234.72% |
| 2020 Q2 | 112.12 Million JPY | -15.28% |
| 2020 Q3 | 222.49 Million JPY | 98.43% |
| 2020 Q4 | 791.15 Million JPY | 255.59% |
| 2020 FY | 1.25 Billion JPY | 99.73% |
| 2019 Q3 | 101.45 Million JPY | 70.8% |
| 2019 Q1 | 119.22 Million JPY | 190.07% |
| 2019 FY | 629.91 Million JPY | 227.79% |
| 2019 Q2 | 59.4 Million JPY | -50.18% |
| 2019 Q4 | -98.23 Million JPY | -196.83% |
| 2018 Q2 | 163.51 Million JPY | 148.14% |
| 2018 Q3 | 108.37 Million JPY | -33.72% |
| 2018 Q1 | -339.65 Million JPY | -397.6% |
| 2018 FY | 192.17 Million JPY | 209.68% |
| 2018 Q4 | -132.36 Million JPY | -222.13% |
| 2017 Q1 | -177.06 Million JPY | -192.25% |
| 2017 FY | -175.2 Million JPY | 65.85% |
| 2017 Q3 | -67.67 Million JPY | -51.72% |
| 2017 Q2 | -44.6 Million JPY | 74.81% |
| 2017 Q4 | 114.13 Million JPY | 268.66% |
| 2016 Q1 | -284.26 Million JPY | -85.63% |
| 2016 Q2 | -338.82 Million JPY | -19.19% |
| 2016 FY | -513.1 Million JPY | 17.66% |
| 2016 Q4 | 191.93 Million JPY | 334.22% |
| 2016 Q3 | -81.94 Million JPY | 75.81% |
| 2015 FY | -623.15 Million JPY | -90.01% |
| 2015 Q2 | -131.75 Million JPY | 15.36% |
| 2015 Q1 | -155.67 Million JPY | -622.47% |
| 2015 Q4 | -153.13 Million JPY | 13.33% |
| 2015 Q3 | -176.68 Million JPY | -34.1% |
| 2014 Q3 | -99.92 Million JPY | 17.03% |
| 2014 FY | -327.95 Million JPY | 55.12% |
| 2014 Q4 | 29.79 Million JPY | 129.82% |
| 2014 Q1 | -137.38 Million JPY | 19.4% |
| 2014 Q2 | -120.43 Million JPY | 12.34% |
| 2013 FY | -730.77 Million JPY | -51.53% |
| 2013 Q4 | -170.44 Million JPY | 52.67% |
| 2013 Q1 | -98.37 Million JPY | 33.51% |
| 2013 Q2 | -101.86 Million JPY | -3.55% |
| 2013 Q3 | -360.09 Million JPY | -253.51% |
| 2012 Q1 | -124.59 Million JPY | 3.13% |
| 2012 Q4 | -147.95 Million JPY | -30.39% |
| 2012 Q3 | -113.47 Million JPY | -17.9% |
| 2012 FY | -482.25 Million JPY | -10.75% |
| 2012 Q2 | -96.24 Million JPY | 22.76% |
| 2011 Q1 | -124.45 Million JPY | -2677.97% |
| 2011 Q3 | -87.27 Million JPY | 8.24% |
| 2011 FY | -435.45 Million JPY | -68.72% |
| 2011 Q4 | -128.61 Million JPY | -47.37% |
| 2011 Q2 | -95.1 Million JPY | 23.58% |
| 2010 Q1 | -136.49 Million JPY | 0.0% |
| 2010 FY | -258.08 Million JPY | 0.0% |
| 2010 Q4 | -4.48 Million JPY | 18.47% |
| 2010 Q3 | -5.49 Million JPY | 95.08% |
| 2010 Q2 | -111.61 Million JPY | 18.23% |
| 2009 Q3 | -150.26 Million JPY | 1.27% |
| 2009 Q1 | -159.6 Million JPY | 52.82% |
| 2009 Q2 | -152.2 Million JPY | 4.63% |
| 2008 FY | -1.36 Billion JPY | -6.79% |
| 2008 Q4 | -338.27 Million JPY | 22.57% |
| 2008 Q3 | -436.86 Million JPY | -1.21% |
| 2008 Q2 | -431.64 Million JPY | 0.0% |
| 2007 FY | -1.27 Billion JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 384 Million JPY | -2007.865% |
| PRISM BioLab Co.,LTD | -526.91 Million JPY | 1636.152% |
| Linical Co., Ltd. | 338.26 Million JPY | -2292.851% |
| Trans Genic Inc. | 4.08 Million JPY | -198044.48% |
| MEDINET Co., Ltd. | -1.43 Billion JPY | 662.899% |
| Soiken Holdings Inc. | -662.2 Million JPY | 1322.314% |
| Cytori Cell Research Institute, Inc. | 138.15 Million JPY | -5758.783% |
| AnGes, Inc. | -7.43 Billion JPY | 208.828% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 728.365% |
| Nxera Pharma Co., Ltd. | -7.19 Billion JPY | 212.529% |
| Immuno-Biological Laboratories Co., Ltd. | 186.69 Million JPY | -4235.545% |
| NanoCarrier Co., Ltd. | -780 Million JPY | 1137.716% |
| Carna Biosciences, Inc. | -1.15 Billion JPY | 802.076% |
| CanBas Co., Ltd. | -1.2 Billion JPY | 769.496% |
| D. Western Therapeutics Institute, Inc. | -812.41 Million JPY | 1096.319% |
| RaQualia Pharma Inc. | -323.66 Million JPY | 2600.819% |
| Chiome Bioscience Inc. | -1.22 Billion JPY | 763.449% |
| Kidswell Bio Corporation | -1.42 Billion JPY | 669.181% |
| PeptiDream Inc. | 3.03 Billion JPY | -166.622% |
| Oncolys BioPharma Inc. | -1.93 Billion JPY | 517.549% |
| Ribomic Inc. | -1.02 Billion JPY | 890.267% |
| SanBio Company Limited | -2.64 Billion JPY | 406.135% |
| Healios K.K. | -3.82 Billion JPY | 311.724% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 792.948% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.48 Billion JPY | 643.38% |
| Delta-Fly Pharma, Inc. | -1.42 Billion JPY | 666.268% |
| StemRIM | -2.02 Billion JPY | 500.307% |
| CellSource Co., Ltd. | 923.14 Million JPY | -776.81% |
| FunPep Company Limited | -933.41 Million JPY | 967.159% |
| Kringle Pharma, Inc. | -854.15 Million JPY | 1047.631% |
| Stella Pharma Corporation | -763.74 Million JPY | 1159.799% |
| TMS Co., Ltd. | -960.04 Million JPY | 943.111% |
| Noile-Immune Biotech Inc. | -1.13 Billion JPY | 816.292% |
| Cuorips Inc. | -632.18 Million JPY | 1380.357% |
| K Pharma,Inc. | 260.33 Million JPY | -3009.208% |
| Takara Bio Inc. | 1.48 Billion JPY | -446.906% |
| ReproCELL Incorporated | -31.41 Million JPY | 25865.405% |
| PhoenixBio Co., Ltd. | 26.37 Million JPY | -30585.427% |
| StemCell Institute Inc. | 310.98 Million JPY | -2502.796% |
| Japan Tissue Engineering Co., Ltd. | 143.16 Million JPY | -5553.6% |
| CellSeed Inc. | -846.53 Million JPY | 1056.158% |